How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey
Authors:
- Kiyoshi ItoKIKiyoshi Ito
- Japanese Gynecologic Oncology Group Disease Committee of Uterine CancerJCJapanese Gynecologic Oncology Group Disease Committee of Uterine Cancer
- 6 March 2015
- journal article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (5) , 997-1004
Abstract
This survey sought to determine Japanese gynecologists’ attitudes concerning administering hormone replacement therapy (HRT) for patients after surgery for endometrial cancer (EC). Eight hundred and eighty-eight members of the Japanese Gynecologic Oncology Group (JGOG) were asked to respond to an anonymous questionnaire on the JGOG website. The survey asked whether or not HRT was to be administered when surgery was performed (including a hysterectomy and bilateral oophorectomy) to treat EC before or after menopause. If HRT was not to be administered, respondents were asked the reason why. Respondents were presented with the same hypothetical patients that were featured in a previous survey in Germany, and differences in the mindsets of Japanese and German physicians were compared. Responses from 363 individuals (response rate 40.9 %) were analyzed. Seventy-eight percent of physicians considered HRT for patients undergoing surgery before menopause. The most prevalent reason of refusal to prescribe HRT was the risk of EC recurrence. Forty-eight percent of physicians considered HRT for patients undergoing surgery after menopause. The most prevalent reasons of refusal of HRT were its limited benefit and the availability of alternative therapies. Sixty-five percent of Japanese physicians responded that they would administer HRT to patients with low risk of recurrence vs. 46 % of physicians in Germany (P < 0.0002). Forty-nine percent of Japanese physicians approved of prescribing HRT for patients with high risk of recurrence vs. 25 % of physicians in Germany (P < 0.0001). Many Japanese gynecologists have a favorable attitude toward prescribing HRT after treatment of EC.Keywords
This publication has 22 references indexed in Scilit:
- Clinical Practice Guidelines for the Management of Patients With Endometrial Cancer in FranceInternational Journal of Gynecological Cancer, 2011
- Impact of surgical menopause on lipid and bone metabolismClimacteric, 2011
- Estrogen replacement therapy after endometrial cancer: a survey of physicians' prescribing practiceClimacteric, 2010
- Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal womenClimacteric, 2010
- Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?International Journal of Gynecological Cancer, 2006
- Randomized Double-Blind Trial of Estrogen Replacement Therapy Versus Placebo in Stage I or II Endometrial Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2006
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Estrogen replacement in surgical stage I and II endometrial cancer survivorsAmerican Journal of Obstetrics and Gynecology, 1996
- Estrogen replacement therapy following treatment for stage I endometrial carcinomaGynecologic Oncology, 1990
- Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line)Journal of Steroid Biochemistry, 1986